Skip to main content

Azenta Value Stock - Dividend - Research Selection

Brooks automation

ISIN: US1143401024 , WKN: 257275

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Brooks Automation, Inc. provides automation and cryogenic solutions for various applications and markets. It operates in two segments, Brooks Semiconductor Solutions Group and Brooks Life Science Systems. The Brooks Semiconductor Solutions Group segment offers critical automated transport, vacuum, and contamination controls solutions and services. Its products include atmospheric and vacuum robots, robotic modules, and tool automation systems that offer precision handling and clean wafer environments; automated cleaning and inspection systems for wafer carriers, as well as reticle pod cleaners and stockers; and vacuum pumping and thermal management solutions for critical process vacuum applications. This segment also offers repair, diagnostic, and installation services, as well as spare parts and productivity enhancement upgrade services. The Brooks Life Science Systems segment provides automated cold storage systems; consumables, including various formats of racks, tubes, caps, plates, and foils; and instruments used for labeling, bar coding, capping, decapping, auditing, sealing, peeling, and piercing tubes and plates. It also provides sample management services, such as on-site and off-site sample storage, cold chain logistics, sample relocation, bio-processing, disaster recovery, and business continuity, as well as project management and consulting. In addition, this segment offers sample intelligence software solutions and customer technology integration; and laboratory work flow scheduling for life science tools and instrument work cells, sample inventory and logistics, environmental and temperature monitoring, and clinical trial and consent management, as well as planning, data management, virtualization, and visualization services. The company serves semiconductor capital equipment and sample management markets for life sciences in approximately 50 countries. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Evercore ISI Group Maintains Outperform on Azenta, Lowers Price Target to $35

2026-04-06
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a Outperform and lowers the price target from $45 to $35.

Wondering what's happening in today's after-hours session?

2026-04-01
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

12 Health Care Stocks Moving In Wednesday's After-Market Session

2026-04-01

Azenta: Life Science Player Fails To Come To Life

2026-03-24
Azenta, Inc. stock trades near $20 with a 0.5x sales valuation and $600M net cash. Click for this updated look at AZTA and see if it is right for you.

Q4 Earnings Highs And Lows: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

2026-03-24
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

2026-03-20
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

3 Unprofitable Stocks That Concern Us

2026-03-19
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Needham Reiterates Buy on Azenta, Maintains $44 Price Target

2026-03-17
Needham analyst David Saxon reiterates Azenta (NASDAQ:AZTA) with a Buy and maintains $44 price target.

Azenta Buys UK Biocentre As Valuation Screens Cheap Despite Weak Momentum

2026-03-16
Azenta (NasdaqGS:AZTA) announced the acquisition of UK Biocentre Limited. The deal is intended to expand Azenta’s biorepository capabilities. UK Biocentre Limited adds a UK based hub focused on large scale sample processing and storage. For investors following Azenta’s role in life sciences infrastructure, this move adds another piece to its biorepository platform. Azenta provides sample exploration and management solutions that support drug discovery, clinical research, and precision...

Has Azenta (AZTA) Fallen Too Far After Recent Share Price Weakness?

2026-03-14
If you are wondering whether Azenta's share price now reflects good value or lingering risks, this article walks through what the numbers actually say about the stock. The shares last closed at US$21.42, and investors have seen returns of an 11.9% decline over 7 days, a 29.7% decline over 30 days, a 35.8% decline year to date, a 41.8% decline over 1 year and a 45.8% decline over 3 years, with a 75.0% decline over 5 years. These moves have put valuation front and center for many shareholders,...